Details of the Drug

General Information of Drug (ID: DM8V75C)

Drug Name
ABIRATERONE
Synonyms Abiraterone (AR inhibitor)
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [1], [2], [3]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 349.5
Topological Polar Surface Area (xlogp) 4.6
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 5 - 14 hours [4]
Metabolism
The drug is metabolized via the esterases [5]
Vd
The volume of distribution (Vd) of drug is 19,669 +/- 13,358 L [6]
Chemical Identifiers
Formula
C24H31NO
IUPAC Name
(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
Canonical SMILES
C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)O
InChI
InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1
InChIKey
GZOSMCIZMLWJML-VJLLXTKPSA-N
Cross-matching ID
PubChem CID
132971
ChEBI ID
CHEBI:68642
CAS Number
154229-19-3
DrugBank ID
DB05812
TTD ID
D02STN
ACDINA ID
D00004

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Steroid 17-alpha-monooxygenase (S17AH) TTRA5BZ CP17A_HUMAN Modulator [2], [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Prostate
The Studied Disease Prostate cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Steroid 17-alpha-monooxygenase (S17AH) DTT CYP17A1 6.87E-01 0.07 0.21
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as ABIRATERONE
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Enzalutamide DMGL19D Major Increased metabolism of ABIRATERONE caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [14]
Darolutamide DMV7YFT Minor Decreased metabolism of ABIRATERONE caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [15]
Coadministration of a Drug Treating the Disease Different from ABIRATERONE (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of ABIRATERONE and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [16]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of ABIRATERONE and Ivosidenib. Acute myeloid leukaemia [2A60] [17]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Midostaurin. Acute myeloid leukaemia [2A60] [18]
Arn-509 DMT81LZ Major Decreased metabolism of ABIRATERONE caused by Arn-509 mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [14]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Gilteritinib. Acute myeloid leukaemia [2A60] [18]
Oliceridine DM6MDCF Major Decreased metabolism of ABIRATERONE caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [19]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of ABIRATERONE and Ivabradine. Angina pectoris [BA40] [18]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of ABIRATERONE and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [20]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of ABIRATERONE and Levalbuterol. Asthma [CA23] [21]
Troleandomycin DMUZNIG Minor Decreased metabolism of ABIRATERONE caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [14]
Cariprazine DMJYDVK Moderate Decreased metabolism of ABIRATERONE caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [22]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of ABIRATERONE and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [23]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Eribulin. Breast cancer [2C60-2C6Y] [18]
Tucatinib DMBESUA Major Decreased metabolism of ABIRATERONE caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [24]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Bosutinib. Breast cancer [2C60-2C6Y] [18]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [18]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Olodaterol. Chronic obstructive pulmonary disease [CA22] [25]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of ABIRATERONE and Vilanterol. Chronic obstructive pulmonary disease [CA22] [21]
Revefenacin DMMP5SI Moderate Decreased clearance of ABIRATERONE due to the transporter inhibition by Revefenacin. Chronic obstructive pulmonary disease [CA22] [26]
Intedanib DMSTA36 Moderate Decreased clearance of ABIRATERONE due to the transporter inhibition by Intedanib. Colorectal cancer [2B91] [27]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of ABIRATERONE and Pasireotide. Cushing syndrome [5A70] [28]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Osilodrostat. Cushing syndrome [5A70] [18]
Lumacaftor DMCLWDJ Major Increased metabolism of ABIRATERONE caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [29]
Ivacaftor DMZC1HS Moderate Decreased metabolism of ABIRATERONE caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [29]
OPC-34712 DMHG57U Major Decreased metabolism of ABIRATERONE caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [30]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of ABIRATERONE caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [31]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Deutetrabenazine. Dystonic disorder [8A02] [18]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Ingrezza. Dystonic disorder [8A02] [18]
Cenobamate DMGOVHA Moderate Increased metabolism of ABIRATERONE caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Stiripentol DMMSDOY Moderate Decreased metabolism of ABIRATERONE caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of ABIRATERONE and Cannabidiol. Epileptic encephalopathy [8A62] [18]
Ripretinib DM958QB Moderate Decreased metabolism of ABIRATERONE caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [16]
Avapritinib DMK2GZX Moderate Decreased metabolism of ABIRATERONE caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [18]
ABT-333 DM7TOWX Moderate Decreased metabolism of ABIRATERONE caused by ABT-333 mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [33]
Boceprevir DMBSHMF Minor Decreased metabolism of ABIRATERONE caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [14]
Brentuximab vedotin DMWLC57 Moderate Decreased metabolism of ABIRATERONE caused by Brentuximab vedotin mediated inhibition of CYP450 enzyme. Hodgkin lymphoma [2B30] [34]
MK-1439 DM215WE Minor Decreased metabolism of ABIRATERONE caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [35]
Cobicistat DM6L4H2 Minor Decreased metabolism of ABIRATERONE caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [14]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [18]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of ABIRATERONE and Teriflunomide. Hyper-lipoproteinaemia [5C80] [28]
Aliskiren DM1BV7W Moderate Decreased metabolism of ABIRATERONE caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [28]
Lesinurad DMUR64T Moderate Decreased metabolism of ABIRATERONE caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [36]
ITI-007 DMUQ1DO Moderate Decreased metabolism of ABIRATERONE caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [37]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of ABIRATERONE and Polyethylene glycol. Irritable bowel syndrome [DD91] [18]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of ABIRATERONE caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [38]
Naloxegol DML0B41 Minor Decreased metabolism of ABIRATERONE caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [39]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of ABIRATERONE and Crizotinib. Lung cancer [2C25] [40]
Brigatinib DM7W94S Moderate Decreased metabolism of ABIRATERONE caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [16]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of ABIRATERONE and Ceritinib. Lung cancer [2C25] [28]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of ABIRATERONE caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [41]
PF-06463922 DMKM7EW Moderate Decreased metabolism of ABIRATERONE caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [42]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of ABIRATERONE and Osimertinib. Lung cancer [2C25] [43]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of ABIRATERONE caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [44]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of ABIRATERONE and Selpercatinib. Lung cancer [2C25] [18]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [18]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of ABIRATERONE and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [45]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of ABIRATERONE and Idelalisib. Mature B-cell leukaemia [2A82] [46]
GDC-0199 DMH0QKA Major Decreased metabolism of ABIRATERONE caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [16]
IPI-145 DMWA24P Moderate Decreased metabolism of ABIRATERONE caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [47]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of ABIRATERONE caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [48]
Arry-162 DM1P6FR Moderate Decreased clearance of ABIRATERONE due to the transporter inhibition by Arry-162. Melanoma [2C30] [16]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of ABIRATERONE and Vemurafenib. Melanoma [2C30] [28]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and LGX818. Melanoma [2C30] [18]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of ABIRATERONE caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [28]
Ubrogepant DM749I3 Moderate Decreased metabolism of ABIRATERONE caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [49]
Rimegepant DMHOAUG Moderate Decreased clearance of ABIRATERONE due to the transporter inhibition by Rimegepant. Migraine [8A80] [50]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of ABIRATERONE and Panobinostat. Multiple myeloma [2A83] [51]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of ABIRATERONE and Fingolimod. Multiple sclerosis [8A40] [28]
Ozanimod DMT6AM2 Major Decreased metabolism of ABIRATERONE caused by Ozanimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [16]
Romidepsin DMT5GNL Moderate Decreased clearance of ABIRATERONE due to the transporter inhibition by Romidepsin. Mycosis fungoides [2B01] [52]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of ABIRATERONE caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [53]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Entrectinib. Non-small cell lung cancer [2C25] [18]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Rucaparib. Ovarian cancer [2C73] [18]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Triclabendazole. Parasitic worm infestation [1F90] [18]
Istradefylline DM20VSK Moderate Decreased metabolism of ABIRATERONE caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [54]
Abametapir DM2RX0I Moderate Decreased metabolism of ABIRATERONE caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [55]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of ABIRATERONE and Macimorelin. Pituitary gland disorder [5A60-5A61] [56]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of ABIRATERONE and Lefamulin. Pneumonia [CA40] [57]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of ABIRATERONE caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [58]
Selexipag DMAHSU0 Moderate Decreased metabolism of ABIRATERONE caused by Selexipag mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [59]
Upadacitinib DM32B5U Moderate Decreased metabolism of ABIRATERONE caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [60]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of ABIRATERONE and Amisulpride. Schizophrenia [6A20] [61]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Asenapine. Schizophrenia [6A20] [18]
LDE225 DMM9F25 Moderate Decreased metabolism of ABIRATERONE caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [62]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of ABIRATERONE caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [18]
Larotrectinib DM26CQR Moderate Decreased metabolism of ABIRATERONE caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [16]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of ABIRATERONE and LEE011. Solid tumour/cancer [2A00-2F9Z] [28]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [18]
Fostamatinib DM6AUHV Moderate Decreased metabolism of ABIRATERONE caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [63]
Lusutrombopag DMH6IKO Moderate Decreased clearance of ABIRATERONE due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [64]
Apixaban DM89JLN Moderate Decreased metabolism of ABIRATERONE caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [18]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of ABIRATERONE and Lenvatinib. Thyroid cancer [2D10] [18]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of ABIRATERONE and Cabozantinib. Thyroid cancer [2D10] [18]
Elagolix DMB2C0E Moderate Decreased metabolism of ABIRATERONE caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [65]
⏷ Show the Full List of 94 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Abiraterone 250 mg tablet 250 mg Oral Tablet Oral
Abiraterone 500 mg tablet 500 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
2 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
3 Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005 Dec;96(9):1241-6.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7 CYP17A1 inhibitors in castration-resistant prostate cancer.Steroids.2015 Mar;95:80-7.
8 Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):115-28.
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2013 Jul 4;14(7):13958-78.
11 Clinical pipeline report, company report or official report of DisperSol Technologies.
12 Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58.
13 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
14 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
15 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
16 Cerner Multum, Inc. "Australian Product Information.".
17 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
20 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
21 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
22 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
23 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
24 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
25 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
26 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
27 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
28 Canadian Pharmacists Association.
29 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
30 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
31 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
32 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
33 Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
34 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
35 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
36 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
37 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
38 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
39 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
40 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
41 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
42 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
43 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
44 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
45 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
46 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
47 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
48 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
49 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
50 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
51 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
52 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
53 Dimartini A "Isoniazid, tricyclics and the ''cheese reaction''." Int Clin Psychopharmacol 10 (1995): 197-8. [PMID: 8675973]
54 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
55 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
56 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
57 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
58 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
59 Product Information. Uptravi (selexipag). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
60 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
61 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
62 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
63 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
64 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
65 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.